Dr. John Cush RheumNow
5 years 4 months ago
Interesting report of 27 pts w/ Jo-1 anti-synthetase syndrome shows that only 4 had classic triad at presentation. 7 patients presented with polyarthritis, 6/7 initially Dx as #RA, Time gap from RA to antisynthetase dx was 3 to 20 years. https://t.co/IMgk3VTr0c
The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.
Dr. John Cush RheumNow
5 years 4 months ago
Dr. Samir V. Parikh from the #SLEEducatorsNetwork discusses the major treatment goals for lupus nephritis and the broader needs of the patient in this program- Defining Treatment Goals for Lupus Nephritis.
Sponsored by GSK US Medical Affairs
https://t.co/f2Y707YDJr https://t.co/lsYDVFWSCS
Dr. John Cush RheumNow
5 years 4 months ago
Good Free 2 part series on Juvenile Fibromyalgia: a chronic diffuse musculoskeletal aching and pain syndrome that may be hard to distinguish from complex regional pain syndrome (CRPS) (ALWAYS CHECK FOR HYPERMOBILITY in Kids) https://t.co/EPmmGVNW63 https://t.co/aP6QHT7tiM
Dr. John Cush RheumNow
5 years 4 months ago
Preliminary results from 600 pt SAVE-MORE trial in severe COVID, anakinra + standard-of-care was 55% better than SOC in preventing death or respiratory failure; and improving Hosp Discharge by 4 days. Anakinra Rx 100mg/day up to 10 days https://t.co/vbpUMQjC1o
Dr. John Cush RheumNow
5 years 4 months ago
Popular Read: Little Effect with Multimodal Treatment of CMC1 Osteoarthritis
https://t.co/6SnJYOK6nu https://t.co/ldTQRujshq
A large prospective cohort study examined the comparative risks of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) and found that, methotrexate (MTX), abatacept (ABA) and TNF inhibitor (TNFi) use were associated with a decreased risk of CV events.
Dr. John Cush RheumNow
5 years 4 months ago
RNL 2021 - Future Therapies in RA: Dr. Roy Fleischmann
https://t.co/icnRaUHo5k
JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.
Dr. John Cush RheumNow
5 years 4 months ago
Meet the #SLEEducatorsNetwork in this disease education series where leading rheumatologists and nephrologists share their perspectives on lupus nephritis.
Sponsored by GSK US Medical Affairs
https://t.co/H9BqP9bW4i https://t.co/VzS95UBJeo
Dr. John Cush RheumNow
5 years 4 months ago
News: Factors Associated with COVID-19 Deaths in Rheumatic Patients
https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy
Dr. John Cush RheumNow
5 years 4 months ago
Levamisole, an anti-helminthic vet drug, is used as a colorless, odorless, adulterant to narcotics, cocaine, fentanyl, etc. Levamisole also causes ANCA+ Vasculitis (small to medium vessels), palpable purpura, agranulocytosis https://t.co/BKoDo2iemJ https://t.co/bSl0eYn0yO
House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.
Dr. John Cush RheumNow
5 years 4 months ago
RheumNow Live is now available for all--check out any panels you may have missed.
https://t.co/jaisVc2kGt https://t.co/Z9m7V96g1g
Dr. John Cush RheumNow
5 years 4 months ago
Listen to Dr. Jack Cush review the news and journal reports from the past week on RheumNow. Our latest podcast is available for download on SoundCloud, Apple and Android carplay.
https://t.co/FvmmOBAjC1 https://t.co/rrZO6jOlKt
